The use of a GLS inhibitor, which can inhibit Glu synthesis in in vitro studies, has also been shown to sensitize gliomas with the IDH1 mutation to oxidative stress by McBrayer et al. [27]. The gene discussed is GLS; the disease is central nervous system cancer.